转移性胰腺癌的治疗进展  

Progress in the treatment of metastatic pancreatic cancer

作　　者：冯治儒 朱晓斐 张火俊 FENG Zhiru;ZHU Xiaofei;ZHANG Huojun(Department of Radiotherapy,the First Affiliated Hospital of Navy Medical University,Shanghai200433,China)

机构地区：[1]海军军医大学第一附属医院放射治疗科,上海200433

出　　处：《中国医药导报》2024年第25期61-66,共6页China Medical Herald

基　　金：国家重点研发计划项目(2022YFC2503701、2022YFC2407105)。

摘　　要：胰腺癌在诊断时通常已进入晚期,发生远处转移。转移性胰腺导管腺癌5年生存率极低,通过全身治疗可控制症状和延长寿命。其治疗手段包括手术、化疗、靶向治疗、免疫治疗及放射治疗等。对转移性胰腺癌,虽然指南不建议进行手术治疗,但寡转移性胰腺癌有别于多发转移胰腺癌,多模式治疗可提高患者的生存率和生活质量,降低毒副作用。本文对转移性胰腺癌相关研究进行综述,并介绍胰腺癌治疗的潜在未来。Pancreatic cancer is frequently diagnosed at an advanced stage with distant metastasis.The five-year survival rate of metastatic pancreatic ductal adenocarcinoma is extremely low,and systemic treatment can control symptoms and prolong lifespan.The treatment methods include surgery,chemotherapy,targeted therapy,immunotherapy,and radiation therapy.For metastatic pancreatic cancer,although the guidelines do not recommend surgical treatment,oligometastatic pancreatic cancer is different from multiple metastatic pancreatic cancer.Multimode treatment can improve the survival rate and quality of life of patients,and reduce side effects.This article reviews the research related to metastatic pancreatic cancer,and introduces the potential future of pancreatic cancer treatment.

关 键 词：胰腺癌 胰腺导管腺癌 转移 治疗 

分 类 号：R735.9[医药卫生—肿瘤]